PGL4.11-COL1A1WT
(Plasmid
#230915)
-
PurposeExpression of human COL1A1 promoter and testing the promoter activity with luciferase assay.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 230915 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonePGL4.11
-
Backbone manufacturerPromega
- Backbone size w/o insert (bp) 4370
- Total vector size (bp) 5350
-
Vector typeMammalian Expression, Bacterial Expression, Luciferase
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameHuman COL1A1 promoter
-
SpeciesH. sapiens (human)
-
Insert Size (bp)980
-
GenBank IDNC_000017.11 (50184096..50201649), complement)
-
Entrez GeneCOL1A1 (a.k.a. CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3, OI4)
- Promoter COL1A1
-
Tag
/ Fusion Protein
- luciferase - Luc2p (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site ACC65I (not destroyed)
- 3′ cloning site XhoI (not destroyed)
- 5′ sequencing primer RVprimer3 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
PGL4.11-COL1A1WT was a gift from Avi Rosenberg (Addgene plasmid # 230915 ; http://n2t.net/addgene:230915 ; RRID:Addgene_230915) -
For your References section:
Bile Acid Receptor Agonist Reverses Transforming Growth Factor-beta1-Mediated Fibrogenesis in Human Induced Pluripotent Stem Cells-Derived Kidney Organoids. Yang X, Delsante M, Daneshpajouhnejad P, Fenaroli P, Mandell KP, Wang X, Takahashi S, Halushka MK, Kopp JB, Levi M, Rosenberg AZ. Lab Invest. 2024 May;104(5):100336. doi: 10.1016/j.labinv.2024.100336. Epub 2024 Jan 22. 10.1016/j.labinv.2024.100336 PubMed 38266922